Menu
In-Depth

Drug policies take on less prominence

It wasn’t that long ago when Bud Selig was tagged as “The Steroid Commissioner,” and it was widely assumed that moniker would follow him to the grave. But just barely three years since the public release of the infamous Mitchell Report, the issue has largely receded from public view.

Just three major league players have failed a test for performance-enhancing drugs since the start of the 2009 season, the most prominent being slugger Manny Ramirez, then of the Los Angeles Dodgers. The number of minor leaguers implicated over the same time is more than 160. But in general, there is a growing feeling that baseball’s numerous corrections to its drug policies over the past half-decade are beginning to have their intended effects.

The issue will take on less prominence during the coming labor negotiations compared with prior rounds, in part because both sides have regularly addressed the drug program since the Mitchell Report’s release. In addition to measures calling for a thorough annual review, new substances that become federally banned automatically become prohibited within baseball’s drug program.

“We’ve been revisiting this topic regularly. That was one of the big positive outcomes of the Mitchell Report,” said Rob Manfred, MLB executive vice president for labor relations and human resources. “So, yes, it’s fair to say, this one relative to some other issues on the table will not be as major.”

Human growth hormone, however, is still a particularly thorny problem. A scientifically validated and scalable urine test for HGH remains elusive, despite plenty of attention and money, including from MLB, being thrown at the problem.

MLB last year began a blood test for HGH in the minors, where there is no players union and such matters are not subject to collective bargaining, and it’s likely the issue will be at least discussed for the major league level. The MLBPA, however, has historically shown great resistance to any sort of blood collection for testing purposes, with concerns including player safety and residual effects upon on-field performance.

SBJ Morning Buzzcast: May 10, 2024

Start your morning with Buzzcast with Austin Karp: A very merry NFL Christmas on Netflix? The Braves and F1 deliver for Liberty Media investors; the WNBA heads to Toronto; and Zelle gets in on team sports sponsorship.

Phoenix Mercury/NBC’s Cindy Brunson, NBA Media Deal, Network Upfronts

On this week’s pod, SBJ’s Austin Karp chats with SBJ NBA writer Tom Friend about the pending NBA media Deal. Cindy Brunson of NBC and Phoenix Mercury is our Big Get this week. The sports broadcasting pioneer talks the upcoming WNBA season. Later in the show, SBJ media writer Mollie Cahillane gets us set for the upcoming network upfronts.

SBJ I Factor: Molly Mazzolini

SBJ I Factor features an interview with Molly Mazzolini. Elevate's Senior Operating Advisor – Design + Strategic Alliances chats with SBJ’s Ross Nethery about the power of taking chances. Mazzolini is a member of the SBJ Game Changers Class of 2016. She shares stories of her career including co-founding sports design consultancy Infinite Scale career journey and how a chance encounter while working at a stationery store launched her career in the sports industry. SBJ I Factor is a monthly podcast offering interviews with sports executives who have been recipients of one of the magazine’s awards.

Shareable URL copied to clipboard!

https://www.sportsbusinessjournal.com/Journal/Issues/2011/04/04/In-Depth/Drug-testing.aspx

Sorry, something went wrong with the copy but here is the link for you.

https://www.sportsbusinessjournal.com/Journal/Issues/2011/04/04/In-Depth/Drug-testing.aspx

CLOSE